ArticleFrontiers in pharmacology2025

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.

Tao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.